Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.49 |
| ▸ | TTR | P02766 | 3/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954995 | 0.86 | TTR (0.42) | CSNK2A1RORCENPP2TTRKMO | |
| SCHEMBL1890521 | 0.80 | TSHR (0.39) | CSNK2A1RORCENPP2LMNASMN1; SMN2 | |
| SCHEMBL29636287 | 0.80 | TSHR (0.39) | CSNK2A1RORCENPP2LMNASMN1; SMN2 | |
| SCHEMBL9812 | 0.79 | ENPP2 (0.60) | ENPP2TTRKMOMEN1KMT2A | |
| SCHEMBL5636990 | 0.79 | ENPP2 (0.42) | ENPP2KMT2A | |
| SCHEMBL9258 | 0.79 | KCNQ3 (0.39) | CSNK2A1RORCENPP2MEN1KMT2A | |
| SCHEMBL29954406 | 0.76 | CA2 (0.39) | ENPP2TTR | |
| SCHEMBL16247112 | 0.76 | KDM4E (0.40) | RORCTTRLMNAKDM4ESMN1; SMN2 | |
| SCHEMBL3720829 | 0.76 | CSNK2A1 (0.56) | CSNK2A1RORCTTRKMOMEN1 | |
| SCHEMBL2316275 | 0.75 | ENPP2 (0.60) | CSNK2A1RORCENPP2TTRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608828-A1 | IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES | Yuhan Corporation (KR) | 2025-09-03 | — | — | EP | claimed |
| CN-119923397-A | Improved process for preparing dimethyl-2, 3-dihydro-1H-indene derivatives | 柳韩洋行 | 2025-05-02 | — | — | CN | claimed |
| WO-2024090919-A1 | IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES | YUHAN CORPORATION (KR) | 2024-05-02 | — | — | WO | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-20260146038-A1 | NOVEL SALT OF DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE AND PROCESSES FOR PREPARING THE SAME | YUHAN CORPORATION (KR) | 2026-05-28 | — | — | US | disclosed |
| EP-4608833-A1 | NOVEL SALT OF DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE AND PROCESSES FOR PREPARING THE SAME | Yuhan Corporation (KR) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608828-A1 | IMPROVED PROCESSES FOR PREPARING DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVES | Yuhan Corporation (KR) | 2025-09-03 | — | — | EP | disclosed |
| CN-119923397-A | Improved process for preparing dimethyl-2, 3-dihydro-1H-indene derivatives | 柳韩洋行 | 2025-05-02 | — | — | CN | disclosed |
| US-20240360095-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| WO-2008062905-A2 | HETEROMONOCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-29 | — | — | WO | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2007104783-A2 | 1,4 -DI SUBSTITUTED 3-CYANO-PYRIDONE DERIVATIVES AND THEIR USE AS POSITIVE MGLUR2-RECEPT0R MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360095-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CSNK2A1 67/4885RORC 1172/4885ENPP2 739/4885 |
| US-20240360156-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | GRIN1, GRIN2C, GRIN2A | CSNK2A1 1266/4885RORC 364/4885ENPP2 1580/4885 |
| US-20260146038-A1 | NOVEL SALT OF DIMETHYL-2,3-DIHYDRO-1H-INDENE DERIVATIVE AND PROCESSES FOR PREPARING THE SAME | ITPR1, ITPR2, CA2 | CSNK2A1 361/4885RORC 2144/4885ENPP2 3929/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | CSNK2A1 1267/4885RORC 311/4885ENPP2 241/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | CSNK2A1 4446/4885RORC 3406/4885ENPP2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.